Pulmonary Edema Therapeutics Market Analysis By Type(Cardiogenic pulmonary edema, Non-cardiogenic pulmonary edema), By Distribution Channel(Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) & Forecast 2023-2032
The global pulmonary edema therapeutics market size was valued at USD 150 million in 2021 and is projected to reach around USD 550 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of heart failure, a major cause of pulmonary edema, an increasing geriatric population, and growing awareness about pulmonary edema are some of the key factors anticipated to drive the market. On the other hand, risks associated with heart treatments and side effects of the treatment are anticipated to hinder the growth of pulmonary edema therapeutics market growth.
The global market for pulmonary edema therapeutics will expand owing to the growing incidence of heart failure, a major cause of pulmonary edema. For example, as per the Places for Infectious prevention and Anticipation, in 2020, about 6.2 million grown-ups in the U.S. had a cardiovascular failure. Moreover, pulmonary edema is a disorder caused by extra fluids in the lungs. The fluids gather in the various air sacs in the lungs making it problematic to breathe. Furthermore, according to the National Heart, Lung and Blood Institute Atherosclerotic Risk in Communities (ARIC) study and Cardiovascular Health Study(CHS) there are around 1,260,000 new and recurrent coronary attacks per year- around 37% people experience coronary attack in a given year die from it. Additionally, the use of intra-ventricular septum contributing to the pumping function of left ventricle, lung parenchyma leading to lung diseases, upsurge in hypertensive crisis, pulmonary shunt and the use of arterial blood gas to measure the quantity of arterial gases such as oxygen and carbon dioxide is additionally driving its market growth.
https://wemarketresearch.com/r....eports/pulmonary-ede
